menu
    • menu
    [{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Atlantia Food Clinical Trials | Signifikans ApS","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Atlantia Food Clinical Trials | Signifikans ApS","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Atlantia Food Clinical Trials | Signifikans ApS"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Aarhus University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Aarhus University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Aarhus University Hospital"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Aarhus University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Aarhus University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Aarhus University Hospital"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"DENMARK","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Chr. Hansen \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Onorach Clinical | CPS Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Onorach Clinical | CPS Research","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Onorach Clinical | CPS Research"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Chr. Hansen"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"B. Adolescentis Bif-038","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chr. Hansen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bif-038","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bif195","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Chr. Hansen"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Bif195","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Bif195","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Bif195","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Bifidobacterium Breve Bif195","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Chr. Hansen"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Lactobacillus GR-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Chr. Hansen"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"University of Copenhagen","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"DENMARK","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ University of Copenhagen","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ University of Copenhagen"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Chr. Hansen","highestDevelopmentStatusID":"10","companyTruncated":"Chr. Hansen \/ Chr. Hansen"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Lactobacillus Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Chr. Hansen"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"University of Copenhagen | Herlev Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"LGG","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ University of Copenhagen | Herlev Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ University of Copenhagen | Herlev Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by Chr. Hansen

    Menu

    Chr. Hansen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Probiotics on Stress in Young Adults

                            Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Stress Disorders, Traumatic.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            May 03, 2023

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B. Adolescentis Bif-038

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Two Probiotic Formulations on Mental Health and Mood Biomarkers in Adults With Depressive Symptoms

                            Details : B. Adolescentis Bif-038 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Depression.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            October 04, 2022

                            Lead Product(s) : B. Adolescentis Bif-038

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bif-038

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population

                            Details : Bif-038 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Inflammation.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            September 07, 2022

                            Lead Product(s) : Bif-038

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Aarhus University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Characterization of the Gastrointestinal Microbiota in Term Newborn Infants After 4 Weeks Supplementation of P...

                            Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 06, 2021

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Aarhus University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Aarhus University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Characterisation of the Gut Microbiota in Term Infants After Maternal Supplementation of Probiotics

                            Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 03, 2021

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Aarhus University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bif195

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : Hvidovre University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's Disease

                            Details : Bif195 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            April 13, 2021

                            Lead Product(s) : Bif195

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : Hvidovre University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifidobacterium Breve Bif195

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Recipient : Hvidovre University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects of Bifidobacterium Breve Bif195 for Diarrhea-predominant Irritable Bowel Syndrome

                            Details : Bifidobacterium Breve Bif195 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 22, 2021

                            Lead Product(s) : Bifidobacterium Breve Bif195

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Recipient : Hvidovre University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bif195

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mapping the MoA Behind GI Protection From Bif195

                            Details : Bif195 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Ulcer.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            June 26, 2020

                            Lead Product(s) : Bif195

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bif195

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of a Probiotic Strain on Ibuprofen-induced GI Damage

                            Details : Bif195 is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Ulcer.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            June 25, 2020

                            Lead Product(s) : Bif195

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Sponsor : University of Copenhagen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of 12 Months Supplementation With a Symbiotic Lozenge on Caries Increment in Healthy Children

                            Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Dental Caries.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            April 26, 2019

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Sponsor : University of Copenhagen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth